Axsome Therapeutics Inc
AXSM182.550USD
+1.710+0.95%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
9.18BValor de mercado
PerdaP/L TTM
Mais detalhes de Axsome Therapeutics Inc Empresa
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Informações de Axsome Therapeutics Inc
Código da empresaAXSM
Nome da EmpresaAxsome Therapeutics Inc
Data de listagemNov 19, 2015
CEOTabuteau (Herriot)
Número de funcionários683
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 19
EndereçoOne World Trade Center, 29Th Floor
CidadeNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10007
Telefone12123323241
Sitehttps://www.axsome.com/
Código da empresaAXSM
Data de listagemNov 19, 2015
CEOTabuteau (Herriot)
Executivos da empresa Axsome Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
57.51K
-13464.00%
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
--
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
--
-5783.00%
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ari Maizel
Mr. Ari Maizel
Chief Commercial Officer
Chief Commercial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
57.51K
-13464.00%
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
--
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
--
-5783.00%
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2023Q3
Por EmpresaUSD
Nome
Receita
Proporção
Auvelitv
136.10M
79.60%
Sunosi
31.61M
18.49%
Symbravo
2.07M
1.21%
Sunosi royality revenue
1.21M
0.71%
Por RegiãoUSD
Nome
Receita
Proporção
United States
169.18M
98.94%
Outside of the United States
1.82M
1.06%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Auvelitv
136.10M
79.60%
Sunosi
31.61M
18.49%
Symbravo
2.07M
1.21%
Sunosi royality revenue
1.21M
0.71%
Distribuição de ações
Atualizado em: dom, 11 de jan
Atualizado em: dom, 11 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Antecip Capital, L.L.C.
14.57%
The Vanguard Group, Inc.
8.24%
BlackRock Institutional Trust Company, N.A.
6.16%
Wellington Management Company, LLP
2.65%
RTW Investments L.P.
2.22%
Outro
66.16%
Investidores
Investidores
Proporção
Antecip Capital, L.L.C.
14.57%
The Vanguard Group, Inc.
8.24%
BlackRock Institutional Trust Company, N.A.
6.16%
Wellington Management Company, LLP
2.65%
RTW Investments L.P.
2.22%
Outro
66.16%
Tipos de investidores
Investidores
Proporção
Investment Advisor
36.67%
Investment Advisor/Hedge Fund
22.02%
Corporation
14.57%
Hedge Fund
11.48%
Research Firm
2.23%
Private Equity
1.35%
Individual Investor
1.13%
Pension Fund
1.09%
Sovereign Wealth Fund
0.93%
Outro
8.52%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
643
38.50M
85.28%
+81.77K
2025Q3
657
38.45M
87.16%
-264.98K
2025Q2
636
38.74M
85.21%
+673.17K
2025Q1
604
38.08M
85.89%
-4.20M
2024Q4
561
37.78M
89.40%
-1.53M
2024Q3
529
39.25M
94.83%
-2.09M
2024Q2
515
41.51M
92.29%
+1.90M
2024Q1
502
39.61M
93.44%
-4.74M
2023Q4
476
39.34M
91.45%
+441.54K
2023Q3
467
38.94M
87.84%
+1.52M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Antecip Capital, L.L.C.
7.34M
14.57%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
4.17M
8.28%
+235.15K
+5.97%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.10M
6.16%
-38.55K
-1.23%
Sep 30, 2025
Wellington Management Company, LLP
1.33M
2.65%
+609.52K
+84.07%
Sep 30, 2025
RTW Investments L.P.
1.12M
2.22%
-398.02K
-26.24%
Sep 30, 2025
Nomura Investment Management Business Trust
1.08M
2.15%
-53.21K
-4.68%
Sep 30, 2025
Geode Capital Management, L.L.C.
997.70K
1.98%
+8.25K
+0.83%
Sep 30, 2025
T. Rowe Price Associates, Inc.
994.50K
1.97%
+418.57K
+72.68%
Sep 30, 2025
Invesco Advisers, Inc.
949.36K
1.88%
+420.83K
+79.62%
Sep 30, 2025
State Street Investment Management (US)
942.96K
1.87%
-15.54K
-1.62%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Neuroscience and Healthcare ETF
4.69%
ALPS Medical Breakthroughs ETF
2.85%
State Street SPDR S&P Pharmaceuticals ETF
2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.73%
iShares U.S. Pharmaceuticals ETF
2.09%
Virtus LifeSci Biotech Products ETF
2.03%
ProShares Ultra Nasdaq Biotechnology
0.92%
iShares Health Innovation Active ETF
0.89%
JPMorgan Healthcare Leaders ETF
0.8%
VanEck Pharmaceutical ETF
0.75%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção4.69%
ALPS Medical Breakthroughs ETF
Proporção2.85%
State Street SPDR S&P Pharmaceuticals ETF
Proporção2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção2.73%
iShares U.S. Pharmaceuticals ETF
Proporção2.09%
Virtus LifeSci Biotech Products ETF
Proporção2.03%
ProShares Ultra Nasdaq Biotechnology
Proporção0.92%
iShares Health Innovation Active ETF
Proporção0.89%
JPMorgan Healthcare Leaders ETF
Proporção0.8%
VanEck Pharmaceutical ETF
Proporção0.75%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
